Clinical trials, including the phase 3 INDIGO (INdividualized Treatment for IDH1-mutant Glioma With Vorasidenib) study, have demonstrated that Vorasidenib significantly prolongs PFS in patients with WHO grade 2 IDH-mutant gliomas, delaying the need for more invasive therapeutic interventions [12]. Here, IDH1 is linked to central nervous system cancer.